Global Market Study on Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics: Rising Prevalence of ADHD and Continuous Innovation by ADHD Drug Manufacturers are Factors Expected to Drive Revenue Growth by 2024 R e s e a r c h About Us Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes. M a r k e t Our offerings include pre-built reports that address every major sale, customized solutions to cater to client-specific needs, and consulting services to offer more value addition. Our nextgeneration research approach for exploring emerging technologies has allowed us to solve the most complex problems of clients. We do not follow a reactive approach, but a pro-active one. Expert analysts at PMR keep a tab on next-generation technologies in their R&D phase and provide the latest insights into these technologies when they are being commercialized. Our ground-breaking approach allows us to deliver market solutions before the technologies reach the market. Our client success stories feature a range of clients from Fortune 500 companies to fast-growing P e r s i s t e n c e startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset. Global Attention Deficit Hyperactivity Disorder Therapeutics Market 2016-2024 R e s e a r c h Report Media Releases Global ADHD Therapeutics Market to Reach US$ 25,054.4 Mn by 2024 end; Rise in Diagnosis Rate of ADHD Expected to Fuel Revenue Growth According to the latest market report published by Persistence Market Research, titled ‘Global ADHD Therapeutics Market: Continuous innovation by drug manufacturers and lucrative marketing strategies to fuel the demand for ADHD Therapeutics during the forecast period (20152024)’, revenue from the global ADHD therapeutics market is expected to expand at a CAGR of 6.2% during forecast period 2015 - 2024. M a r k e t The market is segmented based on drug type, age group, distribution channel, and region. On the basis of drug type, the market has been broadly segmented into stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and non-stimulants (Atomoxetine, Bupropion, Guanfacine, and Clonidine). By drug type, the Lisdexamfetamine Dimesylate drug type sub-segment is expected to register highest CAGR of 15.6% in terms of value over the forecast period. The longer effectiveness of the treatment and easier availability is expected to contribute to its growing adoption. The Lisdexamfetamine Dimesylate drug type sub-segment is expected to reach a market value of US$ 5,682.2 Mn by 2024 end. Stimulants are expected to emerge as the most preferred drug type for both patients P e r s i s t e n c e and physicians globally over the forecast period. The second-most popular drug type subsegment is Amphetamine, expected to register a CAGR of 4.2% during the forecast period. Download Sample of this report @ http://www.persistencemarketresearch.com/samples/4222 Rising prevalence of ADHD owing to the low threshold of diagnostic criteria, increasing awareness regarding ADHD, and shift from ICD-10 to DSM-IV are major factors driving the growth of the global ADHD therapeutics market currently. Other trends driving market growth are increasing concerns among parents and cultural differences towards ADHD, rising ADHD drug usage in adults, and novel drug development. Generic drug manufacturers in the global ADHD therapeutics market are focusing on introducing cheaper and effective generic ADHD drugs to increase market share, the post-patent expiry of prescription drugs. Furthermore, adoption of alternative treatment methods and drug abuse are factors hampering the growth of this market. Global Attention Deficit Hyperactivity Disorder Therapeutics Market 2016-2024 R e s e a r c h M a r k e t This report assesses trends driving each market segments and sub-segments and offers analysis and insights into the potential of ADHD therapeutics therapies in specific regions. North America is estimated to dominate the global ADHD therapeutics market, with a maximum value share of the overall market by the end of 2016. By 2024, North America and Europe markets are expected to account for over four-fifths share of the global ADHD therapeutics market revenue. In terms of value, North America is estimated to be the dominant market, registering a CAGR of 5.9% over the forecast period. For more detailed information (desk of content material), Figures and Tables of the report @ http://www.persistencemarketresearch.com/market-research/attention-deficit- hyperactivity-disorder-therapeutics-market/toc Some key companies covered in this report include Eli Lilly and Company, Novartis AG, Shire PLC, Pfizer, Inc., GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Hisamitsu Pharmaceutical Co., Inc., Impax Laboratories, Inc., Johnson & Johnson, UCB S.A., and Purdue Parma L.P. These companies are primarily focused on enhancing their product portfolio through research and development and on introduction of innovative and cost-effective treatment procedures in order to gain higher market share and to strengthen their respective positions in the global market. Browse through the full Report at http://www.persistencemarketresearch.com/market- P e r s i s t e n c e research/attention-deficit-hyperactivity-disorder-therapeutics-market.asp Global Attention Deficit Hyperactivity Disorder Therapeutics Market 2016-2024 R e s e a r c h About Us: Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes. Our offerings include pre-built reports that address every major sale, customized solutions to M a r k e t cater to client-specific needs, and consulting services to offer more value addition. Our nextgeneration research approach for exploring emerging technologies has allowed us to solve the most complex problems of clients. We do not follow a reactive approach, but a pro-active one. Expert analysts at PMR keep a tab on next-generation technologies in their R&D phase and provide the latest insights into these technologies when they are being commercialized. Our ground-breaking approach allows us to deliver market solutions before the technologies reach the market. Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by P e r s i s t e n c e transforming data from multiple streams into a strategic asset. For information regarding permissions, contact: Persistence Market Research 90 Sate Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 Email: [email protected] Website: http://www.persistencemarketresearch.com/ [email protected] Global Attention Deficit Hyperactivity Disorder Therapeutics Market 2016-2024
existence of comorbid conditions in children leads to underdiagnoses of ADHD and less availability of non-stimulants ADHD drugs in various geographies. These are factors expected to restrain growth of the market over the forecast period.
© Copyright 2024 Paperzz
